Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART

Clinical Immunology

Volumn 139, Issue 1, 2011, Pages 32-39

  Yunihastuti, Evy ^a   Lee, Silvia ^b   Gani, Rino A ^a   Saraswati, Henny ^c   Sundaru, Heru ^a   Lesmana, LA ^a   Sukmana, Nanang ^a   Price, Patricia ^b  

^a CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Antiretroviral therapy; Hepatitis C virus; HIV; Liver enzyme elevation

Indexed keywords

CD30 ANTIGEN; CORE PROTEIN; DIPEPTIDYL PEPTIDASE IV; EFAVIRENZ; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS C ANTIBODY; LAMIVUDINE; NEVIRAPINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; STAVUDINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; BLOOD; COMPLICATION; HEPACIVIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOCYTE ACTIVATION; MALE; RNA, VIRAL; T-LYMPHOCYTES;

EID: 79953003958     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.12.013     Document Type: Article

References (32)

1. Price P., Murdoch D.M., Agarwal U., Lewin S.R., Elliott J.H., French M.A. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin. Microbiol. Rev. 2009, 22:651-663.
2. Dhasmana D.J., Dheda K., Ravn P., Wilkinson R.J., Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68:191-208.
3. French M.A., Price P., Stone S.F. Immune restoration disease after antiretroviral therapy. AIDS 2004, 18:1615-1627.
4. Price P., Morahan G., Huang D., Stone E., Cheong K.Y., Castley A., et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002, 16:2043-2047.
5. Bourgarit A., Carcelain G., Martinez V., Lascoux C., Delcey V., Gicquel B., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006, 20:F1-F7.
6. Tan D.B., Yong Y.K., Tan H.Y., Kamarulzaman A., Tan L.H., Lim A., et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 2008, 9:307-316.
7. John M., Flexman J., French M.A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?. AIDS 1998, 12:2289-2293.
8. Stone S.F., Lee S., Keane N.M., Price P., French M.A. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J. Infect. Dis. 2002, 186:1498-1502.
9. Zylberberg H., Pialoux G., Carnot F., Landau A., Brechot C., Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin. Infect. Dis. 1998, 27:1255-1258.
10. Monsuez J.J., Vittecoq D., Musset L., Alemanni M., Dussaix E., Autran B. Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus. Arthritis Rheum. 1998, 41:740-743.
11. Oliver B.G., Elliott J.H., Price P., Phillips M., Saphonn V., Vun M.C., Kaldor J.M., Cooper D.A., French M.A. Immune restoration disease in HIV patients with Mycobacterium tuberculosis infection is associated with dysregulation of chemokines and cytokines produced by the innate immune system. J. Inf. Dis. 2010, 202:1728-1737.
12. Hamann D., Hilkens C.M., Grogan J.L., Lens S.M., Kapsenberg M.L., Yazdanbakhsh M., van Lier R.A. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J. Immunol. 1996, 156:1387-1391.
13. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. (Lond) 2005, 108:277-292.
14. Stone S.F., Price P., Tay-Kearney M.L., French M.A. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J. Infect. Dis. 2002, 185:1813-1817.
15. Castelain S., Descamps V., Thibault V., Francois C., Bonte D., Morel V., et al. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J. Clin. Virol. 2004, 31:227-234.
16. Bullock G.C., Bruns D.E., Haverstick D.M. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin. Chem. 2002, 48:2147-2154.
17. Utama A., Budiarto B.R., Monasari D., Octavia T.I., Chandra I.S., Gani R.A., et al. Hepatitis C virus genotype in blood donors and associated liver disease in Indonesia. Intervirology 2008, 51:410-416.
18. Crane M., Oliver B., Matthews G., Avihingsanon A., Ubolyam S., Markovska V., Chang J.J., Dore G.J., Price P., Visvanathan K., French M., Ruxrungtham K., Lewin S.R. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J. Infect. Dis. 2009, 199:974-981.
19. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Franzoni F., et al. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig. Liver Dis. 2009, 41:42-48.
20. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Frascerra S., Pampana A., et al. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J. Interferon Cytokine Res. 2009, 29:345-351.
21. Romagnani S., Annunziato F., Manetti R., Almerigogna F., Biagiotti R., Giudizi M.G., et al. Role for CD30 in HIV expression. Immunol. Lett. 1996, 51:83-88.
22. Price P., Keane N.M., Lee S., Lim A.F., McKinnon E.J., French M.A. A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy. Immunology 2006, 119:74-82.
23. Sillanpaa M., Melen K., Porkka P., Fagerlund R., Nevalainen K., Lappalainen M., Julkunen I. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. Virol. J. 2009, 6:84-96.
24. Meintjes G., Rangaka M.X., Maartens G., Rebe K., Morroni C., Pepper D.J., Wilkinson K.A., Wilkinson R.J. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin. Infect. Dis. 2009, 48:667-676.
25. Shelburne S.A., Darcourt J., White A.C., Greenberg S.B., Hamill R.J., Atmar R.L., Visnegarwala F. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005, 40:1049-1052.
26. Labarga P., Soriano V., Vispo M.E., Pinilla J., Martin-Carbonero L., Castellares C., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J. Infect. Dis. 2007, 196:670-676.
27. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. Clin. Infect. Dis. 2005, 40:49-54.
28. Maylin S., Martinot-Peignoux M., Ripault M.P., Moucari R., Cardoso A.C., Boyer N., et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int. 2009, 29:511-517.
29. Zylberberg H., Chaix M.L., Rabian C., Rouzioux C., Aulong B., Brechot C., et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin. Infect. Dis. 1998, 26:1104-1106.
30. Vento S., Garofano T., Renzini C., Casali F., Ferraro T., Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998, 12:116-117.
31. Koutsoudakis G., Herrmann E., Kallis S., Bartenschlager R., Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81:588-598.
32. Chung R.T., Evans S.R., Yang Y., Theodore D., Valdez H., Clark R., et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2009, 16:1915-1923.